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Background: Approximately 50% of patients with major depressive disorder (MDD) do not respond optimally to
antidepressant treatments. Given this is a large proportion of the patient population, pretreatment tests that predict
which patients will respond to which types of treatment could save time, money and patient burden. Brain
imaging offers a means to identify treatment predictors that are grounded in the neurobiology of the treatment
and the pathophysiology of MDD.
Methods/Design: The international Study to Predict Optimized Treatment in Depression is a multi-center, parallel
model, randomized clinical trial with an embedded imaging sub-study to identify such predictors. We focus on
brain circuits implicated in major depressive disorder and its treatment. In the full trial, depressed participants are
randomized to receive escitalopram, sertraline or venlafaxine-XR (open-label). They are assessed using standardized
multiple clinical, cognitive-emotional behavioral, electroencephalographic and genetic measures at baseline and at
eight weeks post-treatment. Overall, 2,016 depressed participants (18 to 65 years old) will enter the study, of whom
a target of 10% will be recruited into the brain imaging sub-study (approximately 67 participants in each treatment
arm) and 67 controls. The imaging sub-study is conducted at the University of Sydney and at Stanford University.
Structural studies include high-resolution three-dimensional T1-weighted, diffusion tensor and T2/Proton Density
scans. Functional studies include standardized functional magnetic resonance imaging (MRI) with three cognitive
tasks (auditory oddball, a continuous performance task, and Go-NoGo) and two emotion tasks (unmasked conscious
and masked non-conscious emotion processing tasks). After eight weeks of treatment, the functional MRI is
repeated with the above tasks. We will establish the methods in the first 30 patients. Then we will identify
predictors in the first half (n = 102), test the findings in the second half, and then extend the analyses to the total
sample.
Trial registration: International Study to Predict Optimized Treatment - in Depression (iSPOT-D). ClinicalTrials.gov,
NCT00693849.
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Major depressive disorder (MDD) is a leading cause of
morbidity, mortality and disability for individuals aged 15
to 44 years [1]. A substantial percentage, (approximately
50%), of patients do not respond to antidepressant treat-
ments and these individuals constitute a large proportion
of the disease burden [2-5]. There is an urgent need for
objective tests that can be obtained before initiating treat-
ment to predict which patients will go on to show a clin-
ical response to treatment, and to identify which type of
treatment is best for the individual patient. Functional and
structural brain imaging offers a means to identify treat-
ment predictors, which are based upon the neurobio-
logical mechanisms of these treatments, and the means to
the pathophysiology of MDD and its subtypes.
The international Study to Predict Optimized Treatment
for Depression (iSPOT-D) [6] is a large, international,
multi-center, parallel model, clinical randomized trial
which seeks to identify factors that predict treatment re-
sponse to three common antidepressants. In iSPOT-D, we
have combined a practical clinical trial design with the use
of brain imaging to identify imaging predictors of
treatment outcome in a real-world setting, along with
other objective measures, such as electrophysiology and
cognitive performance metrics. This paper presents the
background, rationale and methodology for the imaging
sub-study embedded within iSPOT-D.
Recent developments in neuroimaging have yielded
powerful tools that enable quantification of both functional
and static neural connectivity. These tools include diffusion
tensor imaging (DTI), functional magnetic resonance im-
aging (fMRI), resting state fMRI, arterial spin labeling, posi-
tron emission tomography (PET) and high-resolution
cortical mapping techniques that enable the automated, ac-
curate localization of brain regions. Unfortunately, the ma-
jority of studies that have used these techniques to address
treatment prediction in MDD have been underpowered,
employing small cohorts (for example, n = 20 to 30), and
they have typically focused upon a single imaging measure
rather than seek convergence across multiple measures.
Also, to date, no published study has been designed to test
prediction across multiple antidepressants. However, a
considerable body of data has examined the structural and
functional differences that exist between the brains of de-
pressed and non-depressed patients. These studies served
to identify the brain circuits that represent viable targets
for testing predictors of treatment outcome.
The rationale behind the use of three treatment arms in
iSPOT-D is to identify what are the unique and common
brain circuits that modulate response and remission to dif-
ferent types of anti-depressant medications, that is, select-
ive serotonin reuptake inhibitors (SSRIs) versus selective
norepinephrine reuptake inhibitors (SNRIs), or between
the two different types of SSRIs. The receptor-levelpharmacological actions of these medications may not be
the best indicator of the mechanisms by which they lead
to remission of depression, (which may take weeks, unlike
receptor binding), and which is the primary focus of our
analysis. For instance, sertraline and citalopram (the par-
ent compounds for escitalopram) have been found to have
differential effects in animals on hippocampal neuronal
excitability [7], and are also known to differentially alter
behavior in humans that are relevant to the brain circuits
assessed in this study [8]. To date, there have been a few
studies using small samples that examine the functional
imaging predictors of response to individual antidepres-
sants. These studies provide the basis for our rationale for
the study. For example, using emotion activation tasks, de-
pression has been associated with hyper-reactivity of
amygdala circuits, which attenuates the following response
to SSRIs [9-11]. The antidepressant sertraline has similarly
been found to predict response and “normalize” amygdala
hyperactivity and medial prefrontal hypo-activity, which
characterize generalized social phobia, a disorder often co-
morbid with depression [12].
The need for a new mechanism-based approach to diag-
nosing and treating depression has been recognized in
several initiatives. First, the research agenda for DSM-5
(the fifth edition of Diagnostic and Statistical Manual of
Mental Disorders) emphasizes a need to translate neuro-
science research findings into a new classification system
for mental illnesses based on underlying brain circuitry
[13]. Second, the Research Domain Criteria project - a
National Institute of Mental Health initiative - aims to
“develop, for research purposes, new ways of classifying
mental disorders based on dimensions of observable be-
haviour and neurobiological measures” [14,15]. These ob-
jectives have also been touched upon by the recent
Mayflower Action Group Initiative [16]. Imaging tech-
niques, such as magnetic resonance imaging (MRI), pro-
vide a precise window into the circuits that play a role in
the pathogenesis of depression and in the response to
treatment, enabling the quantification of these circuits as
potentially predictive “biomarkers”. The National Insti-
tutes of Health biomarker working group defined a bio-
marker as: “a characteristic that is objectively measured
and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses
to a therapeutic intervention” [17]. There are currently no
clinically useful biomarkers for predicting response to
antidepressant medications [18], a shortfall that the im-
aging sub-study of the iSPOT-D is designed to address.
In this paper, we characterize the key features of the
iSPOT-D imaging sub-study. These features include (i) a
focus on the discovery of imaging biomarkers that are likely
to be clinically useful in the treatment of depression; (ii) a
large and representative sample to achieve generalizable re-
sults, including a large percentage of treatment-naive
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mon, current treatment regimes to provide an understand-
ing of response heterogeneity; (iv) a highly standardized
approach across sites to maximize the power of the data;
and (v) a multi-modality MRI-based approach that provides
convergent evidence that highlights key changes that are
present.
Specifically, the iSPOT-D imaging study will serve to
answer the following key questions:
1. What pre-treatment aspects of brain circuitry
predict and moderate responses to anti-depressants?
2. What aspects of brain circuitry improve following
treatment? We expect partially distinct circuitry to
be involved in predicting response and remission to
different antidepressants.
3. Do these predictive aspects of brain circuitry overlap
with the core imaging features that are seen in
depression when we compare depressed patients to
healthy controls? Drawing on the available evidence
to date, it is expected that those circuits impaired in
depression will also be the mechanism by which
antidepressants exert their mechanism of action.
Thus, we will also assess if depression-related
impairments are “normalized” post-treatment.
4. Are there additional distinctive alterations that
identify specific “subtypes” of depression?
5. Are there associations between the imaging




The structure of the parent iSPOT-D trial has been previ-
ously described in detail [6]. Briefly, it is a multi-center,
international, prospective, parallel model, open-label ran-
domized clinical trial involving 2,016 MDD patients aged 18
to 65 years. There are three treatment arms (escitalopram,
sertraline and venlafaxine-XR) and a control arm, each
with 672 participants. The healthy control participants are
studied only at baseline, while the depressed participants
are studied both at baseline and at eight weeks. The two
sites for the imaging sub-study are the Brain Dynamics
Center, University of Sydney (Sydney) and the Department
of Psychiatry and Behavioral Sciences, Stanford University
(Stanford). A target of 10% of iSPOT-D participants are to
be recruited into the brain imaging sub-study with an over-
all target of approximately 200 participants with MDD (67
in each treatment arm) and 67 in the control group.
Organizational structure/Acquisition sites
The iSPOT-D Executive Committee for the trial oversees
the overall study. Supervision of the study on a day-by
-day basis is performed at the Global CoordinatingCenter and Data Center (Sydney). Coordination of the
study occurs via a Global Trial Coordinator and the ex-
ecutive management team. There are 20 global clinical
sites involved in patient recruitment, though only two
sites are involved in the imaging sub-study (Sydney and
Stanford). The imaging-specific components of the sub-
study are overseen by the senior imaging scientist (MSK)
and the head of the imaging unit (SMG) at the central
imaging site (University of Sydney, Westmead Hospital).
The imaging data obtained at the secondary imaging site
(Stanford University) are monitored at both the point of
acquisition and the central imaging facility.
Study participants
Details of the study inclusion–exclusion criteria are pro-
vided in Williams et al. [6]. In short, the primary diagno-
sis of nonpsychotic MDD is confirmed using the Mini-
International Neuropsychiatric Interview (MINI) [2,3],
according to DSM-IV criteria, and a score ≥16 on the
17-item Hamilton Rating Scale for Depression (HRSD-
17) [4]. All MDD participants are either antidepressant
medication (ADM) naïve or, if they had been previously
prescribed an ADM, had undergone a wash-out period
of at least five half-lives. Healthy control participants are
extensively screened for the absence of Axis I disorders
(using the MINI) and for an HRSD17 score <7.
Imaging participants are selected by sequentially
recruiting patients at the time of enrollment (Figure 1).
Additional MRI-specific exclusion criteria not applied to
the general patients include the standard safety criteria
for MRI scanning: a cardiac pacing/defibrillator device,
claustrophobia, the presence of a magnet-incompatible
metal prosthesis. Demographic information for both the
MDD and control groups in the first 15% of participants
is summarized in Table 1.
Treatment
Participants were randomized to treatment using
PhaseForward’s™ validated, Web-based Interactive Response
Technology. A blocked randomization procedure was
undertaken centrally (block size: 12, across sites). Neither
participants nor investigators/raters were blinded to treat-
ment assignment. The participant’s treating clinician (gen-
eral practitioners and psychiatrists) prescribed ADMs
adjusted dosage according to routine clinical practice.
Ethical considerations
The study is being conducted according to the principles
of the Declaration of Helsinki 2008 and the International
Conference on Harmonization guidelines. Local regula-
tions were also observed: The Australian Therapeutic
Goods Association [19] and the United States Food and
Drug Administration Code of Federal Regulations [20].
Prior to enrollment, the study procedures are fully
Figure 1 Trial flowchart.
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the ethical guidelines of the institutional review board
and written informed consent is obtained.
MRI data acquisition
MRI studies are performed on a 3.0 Tesla GE
SignaTwinspeedHDxtmagnet system (GE Healthcare,
Milwaukee, WI, USA) utilizing an 8-channel (Westmead)
or a 3.0 Tesla GE Discovery MR750magnet system utilizing
a 32-channel (Stanford) phased-array head coil. Specialized
equipment is also used to facilitate the fMRI data collection
(Resonance Technology, Los Angeles, CA, USA) and the
same standardized software is used for the delivery ofTable 1 Demographics for the MDD and control groups
from the first 15% of participants
Measures Controls MDD patients
(n = 30) (n = 30)
Male/Females 12/18 12/18
Right-/Left-handed 26/4 26/4
Mean ± SD Mean ± SD
Age (years) 35.7 ± 14.1 41.2 ± 15.8
Education (years) 15.1 ± 2.8 14.5 ± 3.2
HRSD17 1.3 ± 1.4 19.2 ± 3.1
a
a significant difference with Control group at P <0.001, independent sample
t-test.
HRSD17 17-item Hamilton Rating Scale for Depression; MDD, Major
depressive disorder.functional stimulus (Stimsoft v1.2.1, Neuroscan, El Paso,
TX). All imaging protocols were standardized and cross-
site consistency established for data comparison. Table 2
shows cross-site validation of the T1 spoiled gradient
recalled anatomical protocol using test-retest MRI scans
collected on the same individual scanned at both the
Sydney and Stanford magnetic resonance scanners. Table 3
presents a detailed summary of the acquisition parameters
used. The imaging protocol takes approximately 1 hour
and15 minutes to complete, including patient positioning.
The protocol comprises both functional and structural
MRI components. The full protocol is acquired at the ini-
tial visit; fMRI measures are replicated at the second time
point only (imaging time: 45 minutes).
The structural dataset comprises three scans: a high-
resolution three-dimensional (3D) T1-weighted volume
dataset (1 mm isotropic resolution; repetition time (TR)
8.3 ms; echo time (TE) 3.2 ms; inversion time (TI)
500 ms), DTI data (1.7 × 1.7 in-plane resolution; 2.5 mm
slice thickness; TR 17,000 ms; TE 95 ms) and dual echo
data (0.86 × 0.86 in-plane resolution; 2.5 mm slice thick-
ness; TR 4,000 ms; TE1 6.5 ms; TE2 102 ms).fMRI protocol
The functional dataset involves three cognitive tasks and
two emotion tasks that assess cognitive thinking and emo-
tion processes. The methods have been fully described
Table 2 Cross-site validation of the T1 SPGR anatomical protocol
Intra-class correlation Stanford scan 1 Stanford scan 2 Sydney scan 1 Sydney scan 2
Stanford scan1 1.0
Stanford scan 2 0.999 1.0
Sydney scan1 0.996 0.996 1.0
Sydney scan 2 0.997 0.996 0.996 1.0
Mean gray matter volume (mm3) 7,175 ± 5,527 7,198 ± 5,552 7,193 ± 5,620 7,226 ± 5,668
Intra-class reliability coefficients for volumetric data estimated for 68 brain gray matter regions using the T1 SPGR MRI protocol, using repeat scans done at the
Stanford and Sydney site magnetic resonance scanners. Data show that inter-site scan reliability (for example, Stanford scan 1 - Sydney scan 1) is high and on the
same comparative level as within-site scans (for example, Sydney scan 1 and Sydney scan 2). The mean (+ SD) for gray matter volume across the 68 brain regions
for each scan is also listed.
MRI Magnetic resonance imaging, SD Standard deviation, SPGR Spoiled gradient recalled.
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[21,22].
The cognitive tasks include an auditory oddball task, a
continuous performance task and the Go-NoGo task.
The oddball task is used for evaluating attention modu-
lation. The stimuli consist of 20 high-pitched (1,000 Hz
at 75 dB) ‘target’ tones and 100 lower-pitched (500 Hz at
75 dB) ‘non-target’ tones. In the continuous perform-
ance task, participants view a series of 120 letters (B, C,
D or G) and are instructed to press a button when the
same yellow letter appears twice in a row (a ‘1-back’ de-
sign). To provide a baseline, 40 stimuli are presented in
white, which participants are instructed to ignore. The
Go-NoGo task is used to assess impulsivity (automatic-
ally-generated ‘Go’ responses) versus inhibition (‘NoGo’
responses). ‘Go’ responses are defined by the word
‘press’ presented in GREEN, while ‘NoGo’ responses are
defined by the word ‘press’ presented in RED.
The emotion tasks consist of an unmasked conscious
emotion processing task and a masked non-conscious
emotion processing task. The unmasked emotion process-
ing task [23,24] was developed from a standardized set of
3D evoked facial expressions that depict fear, anger, dis-
gust, sadness, happiness or are neutral [25]. There are a
total of 240 stimuli grouped in blocks of eight faces of the
same emotion, with each emotion block repeated five
times. In the masked non-conscious emotion processing
task, the same set of facial emotion stimuli are used but
each stimulus consists of the emotion face presented non-
consciously (for 10 ms), followed immediately by a neutral
face mask stimulus (for 150 ms). This paired presentation
is designed to prevent conscious awareness of the emotion
stimulus [23,24].
Data processing pipeline
Data are processed using a custom-built automated
pipeline run via scripts in the MATLAB 7.5 software
(MathWorks, Natick, MA, USA). Processing tasks are
performed by a cluster of 18 custom-built computer
nodes running Linux (CENTOS 5.0 distribution); tasks
are assigned, queued and coordinated using a centralcomputer. Specific details of the analysis procedures are
provided below. In summary, the raw DICOM data from
the magnetic resonance scanner are imported using a
script and converted to NIfTI format, then is run through
sequential routines drawn from the Functional MRI of the
Brain (FMRIB) Software Library (FSL) release 4.1.3
(http://www.fmrib.ox.ac.uk/fsl) [26], the Freesurfer image
analysis suite (version 4.3) (documented and freely avail-
able for download online (http://surfer.nmr.mgh.harvard.
edu/) [27], SPM8 software [28] and custom-written rou-
tines that have been described in previous publications
[29-32]. Anonymized data are transferred between the two
imaging sites via a secure ftp connection.
Data storage
Anonymized data are kept in a structured file system
that includes selected intermediate steps to permit the
easy recalculation of data for specific analyses. Off-site
back-ups of data are kept in a secure facility.
Specific MRI analyses
Volumetric and cortical thickness data
Measurements of cortical thickness and volume are made
as described previously [33] using Freesurfer. Briefly, cor-
tical surface reconstruction and volumetric segmentation
are performed in an automated manner on the 3D T1
weighted structural images using the Freesurfer image
analysis suite (version 4.3). The full technical details of
these procedures are described elsewhere [34-45]. All cor-
tical segmentation and labels are manually inspected for
accuracy. Voxel-based morphometry (VBM8) analysis as
implemented in SPM8 is also performed.
DTI processing - tract-based spatial statistical (TBSS) and
tractography analysis
We have previously presented the TBSS-based analysis
used to process our DTI data [46]. DTI data are
preprocessed and analyzed using the Oxford Centre for
FMRIB Diffusion Toolbox and TBSS software tools, part
of the FSL release 4.1.3 (http://www.fmrib.ox.ac.uk/fsl)
[26,47,48]. The raw DTI data for each participant are
Table 3 Detailed summary of the MRI acquisition parameters
Domain Task/Scan type MRI/Autonomic measures Scan protocol/Task description
Structural
scans
T1 Gray/white matter volume Scan protocol: 3D T1 weighted high resolution SPGR MRI
scan, TR = 8.3 ms, TE = 3.2 ms, Flip angle = 110, TI = 500 ms,
NEX = 1, Matrix = 256 × 256, resolution = 1 mm× 1 mm, 180





Fractional Anisotropy (FA), mean (MD), axial
(AD), radial (RD) diffusivity measures for white
matter regions and fiber tracts
Scan protocol: Spin echo DTI echo planar imaging scan, 42
directions, b value = 1,250, TR = 17,000 ms, TE = 95 ms, NEX = 1,
Matrix = 128 × 128, resolution = 1.72 mm × 1.72 mm, 70
contiguous 2.5 mm axial/oblique slices covering the whole brain.
PD/T2 Proton density Scan protocol: 2D Fast Spin echo scan, TR = 4,000 ms, TE1 =
6.4 ms, TE2 = 102 ms, NEX = 1, Matrix = 256 × 256, resolution =
0.86 mm× 0.86 mm, ETL = 16, 70 contiguous 2.5 mm axial/
oblique slices covering whole brain.
T2 structural scan for clinical evaluation
Functional
scans
Oddball Changes in fMRI BOLD signal Scan protocol: Echo planar imaging scan, TR = 2,500 ms, TE =
27.5 ms, Flip angle = 900, NEX = 1, Matrix = 64 × 64, resolution =
3.75 mm× 3.75 mm, 40 contiguous 3.5 mm axial/oblique
slices covering whole brain in each volume, total 120 volumes.
Average heart rate
Average skin conductance Task description: 20 target (1,000 Hz) and 100 nontarget
(50 Hz) tones presented one at a time at 75 db (50 ms each,
ISI = 2.4 seconds).
Continuous performance
test (CPT)
Changes in fMRI BOLD signal Scan protocol: See Oddball protocol
Average heart rate Task description: 120 stimuli are presented (B, C, D or G letters,
for 200 ms each, ISI = 2.3 sec). Sixty were yellow letters to be
held in working memory (no consecutive repetitions), 20 were
1-back sustained attention stimuli (consecutive repetitions of a
letter in yellow) and 40 were perceptual baseline stimuli in
white letters. Participants were measured for the number of
errors or omissions.
Average skin conductance
Go-NoGo Changes in fMRI BOLD signal Scan protocol: See Oddball protocol
Average heart rate Task description: 180 Go stimuli (word ‘press’ in green) and
NoGo stimuli (word ‘press’ in red) each presented sequentially
(500 ms each, ISI = .75 seconds). NoGo stimuli were not
repeated more than three times in a row. Participants were
measured for target detection rate, response time, errors of





Changes in fMRI BOLD signal Scan protocol: See Oddball protocol
Average heart rate Task description: 240 3D evoked standardized facial expressions
that depicted fear, anger, disgust, sadness, happiness or neutral
were presented for 500 ms (ISI = .75 seconds). Stimuli were
grouped into eight faces expressing the same emotion and
were repeated five times in a pseudorandom order.
Participants were assessed for explicit emotion processing for
the ‘Masked’ condition.
Average skin conductance The same set of facial expressions was presented for the
‘Unmasked’ condition; however, backward masking (expression
presented for 10 ms immediately followed by a neutral face for




Phase map Map magnetic field in homogeneities
for EPI distortion correction
Scan protocol: Dual echo MRI scan, TE1 = 10 ms, TE2 = 12.5 ms,
TR = 700 ms, Flip angle = 150, NEX = 1, Matrix = 128 × 128,
40 contiguous 3.5 mm axial/oblique slices.
2D Two-Dimensional, 3D Three-Dimensional, BOLD Blood oxygen level dependent; EPI, Echo-planar imaging, ETL Echo-train length, fMRI Functional magnetic
resonance imaging, ISI Inter-stimulus interval, MRI Magnetic resonance imaging, NEX Number of excitations, PD Proton density, SPGR Spoiled gradient recalled,
TE Echo time, TR Repetition time.
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tortions. Diffusion tensor models are then fitted inde-
pendently for each voxel within the brain mask and
images of fractional anisotropy (FA), mean diffusivity
(MD) and first (λ1), second (λ2) and third Eigen value(λ3) are generated for each participant. FA images from
each participant are then aligned to the FMRIB58_FA
template and transformed into Montreal Neurological
Institute (MNI) 152 1 mm3 standard space using
FMRIB’s nonlinear registration tool FNIRT [49,50]. Next,
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a white matter skeleton representing the centers of all
white matter tracts common to all participants. This FA
skeleton is then thresholded to FA ≥0.3 to include the
major white matter pathways but avoid peripheral tracts
that are more vulnerable to inter-participant variability
and/or partial volume effects with gray matter. Each par-
ticipant’s aligned FA image is then projected onto the
mean FA skeleton. These skeletonized participant data
will be used for performing voxel-wise cross-participant
statistics using permutation testing procedures. Clusters
with significant differences will be labeled using the
Johns Hopkins University International Consortium for
Brain Mapping (JHU ICBM)-DTI-81 white matter labels
atlas [51]. DTI tractography will also be performed using
a multi-fiber diffusion probabilistic model [52]. This
method estimates probability distributions for one or
more fiber populations at each brain voxel. DTI
tractography will allow obtaining a more precise quanti-
fication of the exact orientation and trajectory of WM
fiber tracts.
Functional MRI data analysis
The fMRI analysis procedures are described in detail
elsewhere [22]. In brief, pre-processing and analysis are
performed using SPM8 software (www.fil.ion.ucl.ac.uk/
spm), and involve motion correction, global signal esti-
mation and removal, estimation of normalization trans-
forms from functional to standard MNI space, spatial
smoothing, and then application of a high-pass filter. A
canonical hemodynamic response function (HRF)-con-
volved event-related model is used to model the blood
oxygen level dependent (BOLD) responses for the three
cognitive tasks. An HRF-convolved box-car function is
used to model the BOLD response for both of the emo-
tional processing tasks. Contrast images for each cogni-
tive thinking and emotion processing task are generated
and will be evaluated for voxel-wise comparisons in
BOLD signal for the whole brain. A significance thresh-
old of P <0.05 corrected for multiple comparisons will
be used. Clusters with significant differences will be la-
beled using the Talairach Atlas.
Region of interest definitions
To test specific hypotheses of regional involvement in vol-
ume measurements, fMRI activation tasks and, in the rest-
ing state-fMRI, standardized regions of interest (ROI) have
been defined using the WFU PickAtlas software as a basis
[53]. For selected ROIs without standardized available
masks, custom definitions will be generated using the au-
tomated coordinate extraction method within the
NeuroSynth framework (http://neurosynth.org) [54]. This
environment uses data derived from a machine-learning
technique (naive Bayes classification) to estimate meta-analysis maps of activation maps based on specified search
terms. For DTI data, the JHU white matter atlas will be
used with the TBSS processed data to define white matter
fiber bundles. DTI tractography will also be performed to
define individualized fiber tracts for each participant.
Quality control
MRI data are evaluated at the time of acquisition by the
radiographer. Each MRI study (excluding the fMRI data)
is reported by a radiologist at the site of acquisition (De-
partments of Radiology, Westmead Hospital and Stanford
University) to exclude structural abnormalities. The
imported NIfTI files are visually inspected by the local im-
aging scientist prior to analysis. MRI protocols were stan-
dardized by using careful synchronization of parameters
between sites, scanning of a human phantom on multiple
occasions (MSK, SMG), inter-site visits and ongoing clin-
ical assessment (see Table 2). Routine quality control of
the analysis pipeline was performed using standardized
outputs generated to reflect the quality of motion correc-
tion, image registration and parameter maps for the func-
tional data, fractional anisotropy images for the DTI data
and cortical-subcortical parcellations from Freesurfer for
the structural T1 data.
Analytic approach
Analyses of iSPOT-D imaging data will be conducted in
three phases.
Phase 1 - identification of putative imaging biomarkers for
MDD and subtype classification
Phase 1 includes the first 15% of the MDD cohort tested at
the Sydney site (that is, 30 MDD participants, 30 matched
controls). Analyses will test for the convergence of struc-
tural and functional imaging data for brain circuitry dys-
function in depression (that is, Question 1). These analyses
will replicate existing analyses in the literature using struc-
tural and functional imaging in MDD. We provide out-
comes from these Phase 1 analyses in this report.
Phase 2 - testing of biomarkers, hypothesis generation for
testing against Phase 3 data
Phase 2 includes the first 50% of the MDD cohort tested at
the Sydney site (that is, 102 MDD participants with 34 in
each of the three treatment arms, and 34 matched con-
trols). Analyses will mainly identify baseline brain circuitry
predictors of treatment response, core brain circuitry asso-
ciated with depression and its subtypes, and brain circuits
that change with treatment (that is, Questions 1 through 4).
Phase 3 - replication of early findings, testing associations
in pooled data
Phase 3 includes the full MDD cohort tested at the Syd-
ney site (204 MDD participants, 68 matched controls)
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controls). Analyses will replicate findings from Phase 2
analyses using the entire Sydney cohort and, a separate
replication will be performed in an independent Stanford
cohort. The issue of inter-site variance between the two
imaging sites will be addressed prior to pooling data. We
will first check for systematic differences, if these exist
then they will be modeled out from the analysis, using
site as a covariate. The full cohort will also provide suffi-
cient power to test for associations of imaging measures
with other data available from the iSPOT-D study proto-
col (Question 5).
As a first pass, each of the MRI measures will be ana-
lyzed independently and then combined into a multi-
modal multiple regression analysis.
Power Calculation/Effect size
For analysis of predictive measures (for example, im-
aging measures that predict treatment response or re-
mission due to a specific agent, or predict treatment
resistance assuming that about 50% of participants will
respond [55]) at a statistical power of 80% and an effect
size of 1 standard deviation, the sample size required is
17, (that is, assuming each treatment has N of approxi-
mately 102/3 -- > N = 34; meaning n(R) = 34*.5 = 17 re-
sponders/non-responders). This permits us to analyze
single treatment arms at the 50% data level, enabling
replication of effects with the second 50% of data.
Future exploratory analyses
The high-powered imaging dataset available from the
iSPOT-D study will also provide the opportunity for new
analyses on the cutting edge of the imaging field. Below,
we list some of the novel analyses that we plan to con-
duct using the imaging data.
Whole brain mapping of inter-regional connectivity
using DTI
We quantify inter-regional white matter connectivity by
defining cortical ROIs based on the cortical thickness
parcellation, then determining the number of fibers
connecting each region. Fiber tracking utilizes a multi-
fiber diffusion probabilistic model that estimates probabil-
ity distributions for one or more fiber populations at each
brain voxel [52]. Tractography is performed by sequen-
tially using each of the cortical labels as seed and the
remaining labels as targets. The resulting dataset, a 70 ×
70 inter-regional connectivity matrix for each participant,
will then be subjected to either a pattern-based analysis
(for example, principle components analysis [56] or group
theory [57-60]), or a focused, hypothesis-driven analysis of
specific inter-regional connectivity. This method has been
previously described using Phase 1 data from the first 15%
of the iSPOT-D dataset [56]. We used a pattern analysisapproach to analyze these data to show a 92% accuracy in
characterizing the MDD and control cohorts.
White matter hyperintensity (WMH) analysis
WMH will be measured using a custom, semi-automated
routine using dual-echo data (proton density and spin
echo data) combined with reformatted T1W data in the
axial plane. Initial lesions are selected using OsiriX (http://
www.osirix-viewer.com) [61]; then lesions are quantified
in MATLAB using a multi-modality (T1, T2, Proton Density)
cluster analysis technique (details to be published in a fu-
ture paper). A separate qualitative analysis will also be
performed using the well-validated Schelton’s score [62].
Volume and connectivity analysis of the basal ganglia,
amygdala, thalamus, brainstem and cerebellum
Several novel analytical approaches currently underway
are designed to obtain more detailed connectivity infor-
mation from the deep gray structures and from the cere-
bellum and brainstem structures, along the lines of
previous probabilistic approaches [47].
Resting state fMRI analysis
The fMRI task data will be used to extract resting state
fMRI data. To identify resting state connectivity, the task
effects are modeled within a general linear model frame-
work. These effects are removed and the remaining (re-
sidual) time-series signal is analyzed using SPM8 software.
This method of obtaining resting connectivity from task
fMRI data has been previously established and validated
against non-task-derived resting state data [63,64].
Small world analysis of brain networks
The application of graph theory methods to imaging data
has been useful in extracting sensitive measures of brain
connectivity [57-60]. We will test how these measures are
altered in MDD and test their prognostic value.
Results
Here we present a summary of outcomes to date from
the analysis of Phase 1 using multimodality data (DTI,
fMRI and T1). Using these measures, we test for conver-
gent evidence of core brain circuitry dysfunction in de-
pression, looking at the baseline data for the first 15% of
subjects (prior to treatment). For this analysis, we inves-
tigate the mechanisms of this circuitry, with a specific
focus on the dorsolateral prefrontal cortex, anterior cin-
gulate cortex (ACC) and amygdala.
Our preliminary data (first 15% of subjects) demon-
strate prefrontal dysfunction in MDD, with contributions
from DTI, fMRI and T1 datasets. In the melancholic
MDD subgroup, we have shown alterations of white
matter within the white matter fiber tracts that are asso-
ciated with the prefrontal, limbic and thalamic circuitry
Grieve et al. Trials 2013, 14:224 Page 9 of 13
http://www.trialsjournal.com/content/14/1/224[46,56]. For the same cohort, we also found prefrontal
dysfunction using fMRI data from all five cognitive and
emotion processing tasks: MDD participants were distin-
guished by a distinctive biosignature of hypoactivation of
the dorsolateral prefrontal cortex during working mem-
ory updating and during conscious negative emotion
processing, hyperactivation of the dorsomedial pre-
frontal cortex (ACC) during working memory andFigure 2 Summary of preliminary functional MRI data from the first 1
demonstrating significant hypoactivation of the left amygdala for non-cons
and control groups (left) shows a significant difference (corrected P <0.05).
are shown in the right amygdala, right dorsolateral prefrontal cortex and a
the cingulate bundle was significantly lower (P <0.05) in the MDD group inresponse inhibition cognitive tasks, and hypoactivation
of the dorsomedial prefrontal cortex (ACC) during con-
scious processing of positive emotion tasks [22].
Further data from the first 15% of subjects highlight
the central role of the limbic regions and the ACC in
MDD using convergent evidence from fMRI, structural
T1 and DTI data. The fMRI data and DTI data were an-
alyzed using the methods described in Korgaonkar et al.5% of participants (MDD versus controls). (a) A coronal view (right)
cious negative emotion processing. Comparison between the MDD
(b) Significant reductions in gray matter volume (uncorrected P <0.05)
nterior cingulate regions. (c) FA in the fornix and cingulum portion of
comparison to controls.
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http://www.trialsjournal.com/content/14/1/224[22,46], while the structural T1 weighted data were ana-
lyzed using the methods described above. We tested for
MDD-Control group differences in the fMRI BOLD signal
and gray matter volume in the ACC and amygdala, as well
as for FA differences in two white matter fiber bundles as-
sociated with these regions, that is, the cingulum cingulate
bundle and fornix respectively. A significant difference
(corrected P <0.05) between the MDD and control group
was found in the left amygdala for non-conscious negative
emotion processing, with hypoactivation of this region
seen in the MDD group (Figure 2a) (significant differences
in ACC and DLPFC are already reported in [22]). A reduc-
tion in gray matter volume (uncorrected P <0.05) was also
seen in both the amygdala and ACC regions (Figure 2b).
FA in the cingulum cingulate bundle was also found to be
significantly reduced (P <0.05) in the MDD group in com-
parison to controls (Figure 2c).Discussion
There are currently no clinically useful predictors of
MDD response or remission with the antidepressants
escitalopram, sertraline or venlafaxine-XR. MRI mea-
sures of brain circuitry and function hold great potential
as “biomarkers” in psychiatric disease; however, there is
a lack of data regarding their use in predicting treatment
response in MDD. The imaging sub-study of iSPOT-D
seeks to provide high-level evidence regarding which as-
pects of brain circuitry predict and moderate response
to these antidepressants.
In this paper, we have outlined the protocol and ration-
ale for the imaging sub-study of iSPOT-D. We summa-
rized the already-published outcomes from the first 15%
of the data and also presented some additional supportive
data. These multimodality outcomes provide the first con-
vergent evidence of dysregulation in both the activation
and connectivity of the prefrontal-limbic circuitry in de-
pression. Analysis of the 50% data will focus on predictive
measures of treatment response, with an a priori focus on
these circuits. The careful design of our study, its power
and the focus on multimodality data maximize the possi-
bility of achieving our aim of generating imaging-based
metrics that have clinically relevant predictive value.
At the completion of iSPOT-D and the imaging sub-
study delineated here, we will investigate how imaging
measures of brain circuitry relate to other clinical, gen-
etic, behavioral and physiological units of analysis in
order to test combined predictors of treatment outcome.Trial status
Enrollment is ongoing. Final data collection date for pri-
mary outcome measure is estimated to be August 2013.
Study completion date is estimated to be December 2013.Abbreviations
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